Literature DB >> 10849055

Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil.

S Mendonça1, C Ecclissato, M S Sartori, A P Godoy, R A Guerzoni, M Degger, J Pedrazzoli.   

Abstract

BACKGROUND: Helicobacter pylori infection is associated with a wide range of digestive diseases and is very prevalent in developing countries, although few data exist on the susceptibility of H. pylori to antimicrobials commonly used in eradication schedules in these countries. The aim of this study was to evaluate the resistance of H. pylori to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in dyspeptic Brazilian patients. Material and Methods. Ninety consecutive H. pylori-positive patients were enrolled. Resistance was evaluated by an agar dilution test.
RESULTS: Resistance to metronidazole was detected in 38 patients (42%); to amoxicillin in 26 individuals (29%); to clarithromycin in 6 patients (7%); to tetracycline in 6 patients (7%); and to furazolidone in 4 individuals (4%). Thirteen strains were resistant to two agents, and eight strains were resistant to three antimicrobials.
CONCLUSIONS: These results confirm the need for culture and susceptibility testing to define H. pylori resistance patterns in particular geographical areas before the general use of an eradication schedule. They also suggest the possibility of resistance to such antimicrobials as amoxicillin or tetracycline in geographical areas with a high prevalence of H. pylori infection and still not fully evaluated for antimicrobial susceptibility.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10849055     DOI: 10.1046/j.1523-5378.2000.00011.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  46 in total

1.  Antibiotic susceptibility of Helicobacter pylori clinical isolates: comparative evaluation of disk-diffusion and E-test methods.

Authors:  K K Mishra; S Srivastava; A Garg; A Ayyagari
Journal:  Curr Microbiol       Date:  2006-09-12       Impact factor: 2.188

2.  In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection.

Authors:  Osamu Kamoda; Kinsei Anzai; Jun-ichi Mizoguchi; Masatoshi Shiojiri; Toshiharu Yanagi; Takeshi Nishino; Shigeru Kamiya
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer.

Authors:  Maria Aparecida Mesquita; Sonia Letícia Silva Lorena; Jazon Romilson Souza Almeida; Ciro Garcia Montes; Fábio Guerrazzi; Luciana T Campos; José Murilo Rubiota Zeitune
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

4.  Antibiotic resistance of Helicobacter pylori strains in Japanese children.

Authors:  Seiichi Kato; Shigeru Fujimura; Hirokazu Udagawa; Toshiaki Shimizu; Shunichi Maisawa; Kyoko Ozawa; Kazuie Iinuma
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

5.  Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial.

Authors:  Seyed Amir Mirbagheri; Mehrdad Hasibi; Mehdi Abouzari; Armin Rashidi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

Review 6.  Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection?

Authors:  Zhi-Fa Lv; Fu-Cai Wang; Hui-Lie Zheng; Ben Wang; Yong Xie; Xiao-Jiang Zhou; Nong-Hua Lv
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

7.  Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

Authors:  Kathleen R Jones; Jeong-Heon Cha; D Scott Merrell
Journal:  Curr Drug ther       Date:  2008-09-01

8.  Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.

Authors:  Guilherme-Eduardo-Goncalves Felga; Fernando-Marcuz Silva; Ricardo-Correa Barbuti; Tomas Navarro-Rodriguez; Schlioma Zaterka; Jaime-Natan Eisig
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

9.  Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy.

Authors:  Zaigham Abbas; Javed Yakoob; Shahab Abid; Wasim Jafri; Muhammad Islam; Zahid Azam; Imran Hilal
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

10.  Comparison of Three 7-Day Pantoprazole-Based Helicobacter pylori Eradication Regimens in a Mexican Population with High Metronidazole Resistance.

Authors:  M Dehesa; J Larisch; M Dibildox; M Di Silvio; L H Lopez; E Ramirez-Barba; J Torres
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.